Five diverse patient case studies illustrate how tumor-derived DNA in CSF using Belay Summit can help the clinician diagnose, classify, and formulate treatment plans for patients with primary and secondary CNS tumors.
Patient tests negative for TP53 variant in hereditary cancer panel and negative in CSF cytology. Summit detects TP53 variant, informing diagnosis of lymphocytic neoplasm. Read more…
Patient has brain stem lesions, contraindicating biopsy. Summit detects H3-3A K28 variant that informs treatment and provides clinical trial options. Read more…
Patient with vitreoretinal lymphoma has negative CSF cytology and shows no intracranial spread on MRI. Summit detects MYD88 L265P, confirming broader CNS involvement, thus indicating systemic vs localized therapy. Serial testing with Summit for variant allele frequency (VAF) indicates patient response to therapy. Read more…
Patient with renal cancer shows lesion on MRI suggestive of brain metastasis. Summit detects TP53 variant confirming the differential diagnosis of choroid plexus carcinoma and provides five clinical trials. Read more…
Patient with lung cancer and brain metastasis has suspected leptomeningeal disease. Summit detects variants consistent with LMD diagnosis. Report provides six FDA-approved targeted therapies. Read more…
